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Introduction: Systemic mycosis due to the non-Candida 
species has emerged as a serious opportunistic com- 
plication in transplant recipients. 
Methods and results: During 01, 1993, to 01, 2001, in 
48 (65.8%) patients a non-Candida fungal species was 
isolated from central venous blood culture specimen. 
Median age in 36 male and 12 female was 31, f s.d 16.6 
y. In 35, partially matched (19 had 3 human leukocyte 
antigen (HLA)-antigen mismatched) marrow graft from 
a related donor (PMRD), 5 matched, unrelated donor 
(MUD), 3 matched, sibling donor (MSD), and in 5, 
autologous transplantation was performed. All patients 
with PMRD and 4 MUD underwent T-cell depleted 
transplantation. Acute leukemia was present in 21 
(ALL 11; AML lo), chronic leukemia in 12 (CML 11; 
CLL l), lymphoma in six (NHL 4; HD 2), MDS in 4, 
multiple myeloma 2 and 12 had other conditions. And 
48.9% had profound neutropenia (ANCllOO cells/(L). 
Nine patients were receiving immunosuppressive therapy 
for acute graft-versus-host disease. The incidence of 
non-Candida fungemia in PMRD was 9.2% (35/379); 
MUD 14.7% (5/34); MSD 4.9% (3/61), and in recipients 
of autologous graft was 4.3% (5/115). In 3 individuals, 
more than one fungal species was isolated during the 
same hospitalization. Among 55 episodes, 6 Aspergillus 
spp. (1 A. fumigatus, 2 A. niger, 1 A. flavus), 3 
Dematiaceous molds (1 Alternaria, 1 Curvularia), and 2 
Trichosporon beigelii were treated as systemic fungal 
infection. Whereas, 20 Penicillium, 8 Cladosporium, 7 
Geotrichum candidum, 3 Chrysosporium, 2 Aureo- 
basidium, and one episode each of Epicoecum, Paecilo- 
myces, Sporoblomyces, and Saccharomyces cerevisiae 
were considered non-pathogenic. In 7 patients (14.6%) 
death was attributed to fungal infection. A patient with 
Aspergillus non-fumigatus spp. succumbed to hemato- 
genous dissemination 11 days after the initial episode. 
In the non-pathogen group, 3 patients with Penicillium, 
and a single patient with G. candidum, Chrysosporium, 
and Epicoecum each (16.2%) died within median 
9.5ks.d 10 days after the initial positive fungal blood 
culture. 
Conclusions: Systemic infection due to pathogenic 
non Candida species had low-attributable mortality 
(9%) in this setting. Molds with low intrinsic virulence, 
and frequent environmental contaminants may occas- 
ionally lead to fatal systemic infection in patients at 
risk. 
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We present three cases of Aspergillus endogenous endo- 
phthalmitis in immunocompromised patients. Case 1 is 
a 56 year old man with emphysema who developed 
endogenous Aspergillus endophthalmitis after brief 
treatment with corticosteroids.The eye required enuclea- 
tion. Case 2 is a 57 year old woman with bronchiolitis 
obliterans organizing pneumonia (BOOP) treated with 
corticosteroids who had Aspergillus endocarditis and 
endogenous Aspergillus endophthalmitis. She died of 
a cerebral hemorrhage. Case 3 is a 73 year old man 
with BOOP on corticosteroids who developed invasive 
pulmonary aspergillosis with dissemination to the eye. In 
an effort to define better ways to identify patients at risk 
for Aspergillus endogenous endophthalmitis and to 
determine optimal diagnostic and treatment strategies, 
we reviewed 86 cases of endogenous Aspergillus endo- 
phthalmitis reported since 1949. Predisposing medical 
conditions were present in 94%. Immunosuppression 
including organ transplantation, steroids, or malignancy 
was present in 49%, intravenous drug use was noted in 
27%, and underlying lung disease in 17%. Pars plana 
vitrectomy appears to be the highest-yield procedure for 
establishing the diagnosis. 90% of vitrectomy specimens 
yielded Aspergillus compared with 54% of vitreous 
aspirates. A. fumigatus caused infection in 51% and A. 
JEavus in 26%. Outcomes were generally poor. Only 7 of 
the 84 patients (8%) with posterior chamber involve- 
ment regained useful vision. Treatment with intravenous 
amphotericin B combined with intravitreal injection of 
amphotericin B and vitrectomy appears to be the most 
efficacious therapy. Six of 7 patients reported to have 
regained useful vision had received such treatment. 
Aspergillus endogenous endophthalmitis is difficult to 
diagnose and treat effectively. The best strategy appears 
to include diagnostic vitrectomy in high-risk individuals 
combined with intravitreal and systemic amphotericin B 
for patients in whom Aspergillus spp. are identified. 
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Background: The search for safe, effective treatment of 
invasive fungal infections has yielded novel antifungals, 
including the triazole voriconazole (Pfizer), liposomal 
preparations of amphotericin such as Abelcet (Lipo- 
some), the echinocandin micafungin (FK) (Fujisawa) 
and the pneumocandin caspofungin (MK) (Merck). 
These new antifungals are active against pathogenic 
